Last reviewed · How we verify
Bacteriophages
At a glance
| Generic name | Bacteriophages |
|---|---|
| Sponsor | Southwest Regional Wound Care Center |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BacterioPHAGE for Gastrointestinal Health 2 Study (NA)
- Phage Safety Cohort Study (N/A)
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient Study (Phase 1)
- Investigation of Norovirus Infection Incidence According to the Presence of Fecal Bacteriophages After Oyster Consumption : Randomized Controlled Clinical Trial - VIROYSTER (NA)
- Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) (Phase 1)
- A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer (Phase 1)
- Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii, P. Aeruginosa or S. Aureus (N/A)
- A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy And VRE-Colonized Subjects (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bacteriophages CI brief — competitive landscape report
- Bacteriophages updates RSS · CI watch RSS
- Southwest Regional Wound Care Center portfolio CI